BACKGROUND Cannabis was used for cancer patients as early as about 2500 years ago. Experimental studies demonstrated tumor-inhibiting activities of various cannabinoids more than 40 years ago. In view of the status of tetrahydrocannabinol (THC) as a regulated substance, non-psychotomimetic cannabidiol (CBD) is of particular importance. OBJECTIVES Efficacy of pure CBD in various animal models as well as initial results (case reports) from patients. METHODS Review of the literature on animal experiments and observations in humans. RESULTS Preclinical studies, particularly recent ones, including numerous animal models of tumors, unanimously suggest the therapeutic efficacy of CBD. In isolated combination studies, synergistic effects were generally observed. In addition, CBD may potentially play a role in the palliative care of patients, especially concerning symptoms such as pain, insomnia, anxiety, and depression. Further human studies are warranted.

中文翻译：

---

Cannabidiol bei Tumorerkrankungen

背景技术早在大约 2500 年前，大麻就被用于癌症患者。40 多年前，实验研究证明了各种大麻素的肿瘤抑制活性。鉴于四氢大麻酚 (THC) 作为受管制物质的地位，非拟精神病大麻二酚 (CBD) 尤为重要。目标纯 CBD 在各种动物模型中的功效以及来自患者的初步结果（病例报告）。方法 回顾有关动物实验和人类观察的文献。结果 临床前研究，特别是最近的研究，包括许多肿瘤动物模型，一致表明 CBD 的治疗效果。在单独的联合研究中，通常观察到协同效应。此外，CBD 可能在患者的姑息治疗中发挥作用，尤其是关于疼痛、失眠、焦虑和抑郁等症状。进一步的人体研究是有必要的。